论文部分内容阅读
目的探讨联合检测血绒毛膜促性腺激素(β-HCG)、血清孕酮(P)水平在异位妊娠(EP)保守治疗中的临床意义。方法用荧光免疫法对85例EP患者用甲氨蝶呤、甲氨蝶呤联合米非司酮治疗前后的β-HCG、P水平进行联合检测。结果异位妊娠(EP)P≥15.9nmol/L的患者46分为A、B组,A组采用米非司酮联合MTX治疗,B组单用MTX治疗,A组与B组血HCG下降有显著差异,A组EP治疗成功率明显高与B组。P<15.9nmol/L的患者39分为A、B组,A组采用米非司酮联合MTX治疗,B组单用MTX治疗,A组与B组血HCG下降无显著差异,EP治疗成功率无明显差异。结论β-HCG、P联合监测在指导EP治疗方案方面具有重要意义。
Objective To investigate the clinical significance of combined detection of serum human chorionic gonadotropin (β-HCG) and serum progesterone (P) in the conservative treatment of ectopic pregnancy (EP). Methods Fluorescence immunoassay was used to detect the levels of β-HCG and P before and after treatment with methotrexate, methotrexate and mifepristone in 85 patients with EP. Results 46 patients with ectopic pregnancy (EP) P≥15.9nmol / L were divided into A and B groups, A group treated with mifepristone combined with MTX, B group treated with MTX alone, A group and B group decreased blood HCG Significant difference, A group of EP treatment was significantly higher in the success rate with the B group. 39 patients with P <15.9nmol / L were divided into group A and group B. Group A was treated with mifepristone combined with MTX. Group B was treated with MTX alone. There was no significant difference in serum HCG between group A and group B. The success rate of EP treatment No significant difference. Conclusion The combined monitoring of β-HCG and P is of great significance in guiding the treatment of EP.